Live Breaking News & Updates on Eleanor perkin

Stay informed with the latest breaking news from Eleanor perkin on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Eleanor perkin and stay connected to the pulse of your community

Sosei Heptares Doses First Subject in Phase I Trial with HTL0048149, a First-in-Class GPR52 Agonist for Schizophrenia

HTL'149 has been designed as a once-daily oral treatment to address positive and negative symptoms and cognitive impairment in schizophrenia patients without the adverse effects typically associated with existing

Tokyo , Japan , United-kingdom , Cambridge , Cambridgeshire , Shinichiro-nishishita , Maya-bennison , Neurocrine-biosciences , Matt-barnes , Frazer-hall , Hironoshin-nomura , Eleanor-perkin

Sosei Heptares Provides Update on Lotiglipron Development

Sosei Heptares Provides Update on Lotiglipron Development
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United-kingdom , Japan , Cambridge , Cambridgeshire , Tokyo , Sosei-heptare , Chris-cargill , Maya-bennison , Genentech-roche , Shinichiro-nishishita , Sosei-heptares , Frazer-hall

Immodulon Further Strengthens Leadership Team with the Appointments of Richard Couch as Chief Technology Officer and Owen Vaughan as Chief Regulatory Officer

Immodulon Further Strengthens Leadership Team with the Appointments of Richard Couch as Chief Technology Officer and Owen Vaughan as Chief Regulatory Officer
itbusinessnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itbusinessnet.com Daily Mail and Mail on Sunday newspapers.

London , City-of , United-kingdom , Uxbridge , Hillingdon , Frazer-hall , Owen-vaughan , Eleanor-perkin , Gertjan-bartlema , Josefine-roemmler-zehrer , Peter-greaney , Sandi-greenwood

Sosei Heptares Provides Update on Lotiglipron Development

Tokyo, Japan and Cambridge, UK, 27 June 2023 – Sosei Group Corporation (“the Company”; TSE: 4565) notes the decision by its partner Pfizer to prioritize...

Japan , United-kingdom , Cambridge , Cambridgeshire , Tokyo , Sosei-heptare , Eleanor-perkin , Hironoshin-nomura , Frazer-hall , Shinichiro-nishishita , Neurocrine-biosciences , Chris-cargill

Molecure Files an Investigational New Drug (IND) application for lead clinical candidate OATD-01 with U.S. FDA ahead of a planned Phase 2 pulmonary sarcoidosis study

Molecure Files an Investigational New Drug (IND) application for lead clinical candidate OATD-01 with U.S. FDA ahead of a planned Phase 2 pulmonary sarcoidosis study
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United-states , Warsaw , L67- , Poland , Polish , Frazer-hall , Molecure-sa , Samson-fung , Marcin-szumowski , Sandi-greenwood , Eleanor-perkin , Warsaw-stock-exchange

Sosei Heptares Operational Highlights and Consolidated Results for the First Quarter 2023

Sosei Heptares Operational Highlights and Consolidated Results for the First Quarter 2023
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Cambridge , Cambridgeshire , United-kingdom , Japan , Tokyo , Sosei-heptareswe , Neurocrine-biosciences , Shinichiro-nishishita , Frazer-hall , Chris-cargill , Sosei-heptares , Staffmaya-bennison

Sosei Heptares Operational Highlights and Consolidated

Tokyo, Japan and Cambridge, UK, 12 May 2023 – Sosei Group Corporation (“the Company”; TSE: 4565) provides an update on operational activities and reports...

Tokyo , Japan , United-kingdom , Cambridge , Cambridgeshire , Genentech-roche , Neurocrine-biosciences , Maya-bennison , Sosei-heptare , Tempero-bio , Candelle-chong , Hironoshin-nomura

Oxford BioTherapeutics announces Phase 1b trial in collaboration with GORTEC to investigate OBT076 in Adenoid Cystic Carcinoma (ACC) of the head and neck

Oxford BioTherapeutics announces Phase 1b trial in collaboration with GORTEC to investigate OBT076 in Adenoid Cystic Carcinoma (ACC) of the head and neck
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Belgium , France , United-kingdom , Spain , Switzerland , Germany , United-states , Wuxi , Jiangsu , China , Sylvie-berrebi , Oxford-biotherapeutics

Sosei Heptares Announces Change of Market Listing Segment to the Tokyo Stock Exchange Prime Market

Sosei Heptares Announces Change of Market Listing Segment to the Tokyo Stock Exchange Prime Market
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Japan , Tokyo , Cambridge , Cambridgeshire , United-kingdom , Eleanor-perkin , Frazer-hall , Chris-cargill , Neurocrine-biosciences , Sosei-heptares , Hironoshin-nomura , Disclosurescandelle-chong

Sosei Heptares Receives Approval for Change of Market Listing Segment to the Tokyo Stock Exchange Prime Market

08.03.2023 - Tokyo, Japan and Cambridge, UK, 8 March 2023 – Sosei Group Corporation (“the Company”; TSE: 4565), the world leader in G protein-coupled receptor (GPCR) focused structure-based drug design (SBDD) and development, is pleased to announce it has ...

Japan , Tokyo , Cambridge , Cambridgeshire , United-kingdom , Eleanor-perkin , Frazer-hall , Neurocrine-biosciences , Sosei-heptares , Hironoshin-nomura , Candelle-chong , Genentech-roche